These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21183724)

  • 1. Efficacy and safety of rituximab in pediatric neuromyelitis optica.
    Mahmood NA; Silver K; Onel K; Ko M; Javed A
    J Child Neurol; 2011 Feb; 26(2):244-7. PubMed ID: 21183724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
    Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of pediatric neuromyelitis optica.
    Lotze TE; Northrop JL; Hutton GJ; Ross B; Schiffman JS; Hunter JV
    Pediatrics; 2008 Nov; 122(5):e1039-47. PubMed ID: 18838462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab use in pediatric central demyelinating disease.
    Beres SJ; Graves J; Waubant E
    Pediatr Neurol; 2014 Jul; 51(1):114-8. PubMed ID: 24768216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
    He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
    Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rituximab on relapse rate and disability in neuromyelitis optica.
    Bedi GS; Brown AD; Delgado SR; Usmani N; Lam BL; Sheremata WA
    Mult Scler; 2011 Oct; 17(10):1225-30. PubMed ID: 21622594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success.
    Greenberg BM; Graves D; Remington G; Hardeman P; Mann M; Karandikar N; Stuve O; Monson N; Frohman E
    Mult Scler; 2012 Jul; 18(7):1022-6. PubMed ID: 22261118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
    Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
    J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive neuromyelitis optica: a pediatric case report and 6-year follow-up.
    Maraş H; Kara B; Anık Y
    Pediatr Neurol; 2013 Sep; 49(3):198-202. PubMed ID: 23831249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.
    Jacob A; Weinshenker BG; Violich I; McLinskey N; Krupp L; Fox RJ; Wingerchuk DM; Boggild M; Constantinescu CS; Miller A; De Angelis T; Matiello M; Cree BA
    Arch Neurol; 2008 Nov; 65(11):1443-8. PubMed ID: 18779415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions.
    Pohl D
    Curr Opin Neurol; 2008 Jun; 21(3):366-72. PubMed ID: 18451724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options in neuromyelitis optica spectrum disorders.
    Kitley J; Palace J
    Expert Rev Neurother; 2016; 16(3):319-29. PubMed ID: 26840802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open label study of the effects of rituximab in neuromyelitis optica.
    Cree BA; Lamb S; Morgan K; Chen A; Waubant E; Genain C
    Neurology; 2005 Apr; 64(7):1270-2. PubMed ID: 15824362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels.
    Nakashima I; Takahashi T; Cree BA; Kim HJ; Suzuki C; Genain CP; Vincent T; Fujihara K; Itoyama Y; Bar-Or A
    J Clin Neurosci; 2011 Jul; 18(7):997-8. PubMed ID: 21565508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromyelitis optica in a child with atypical onset and severe outcome.
    Milani N; Zibordi F; Erbetta A; Pollo B; Angelini L
    Neuropediatrics; 2004 Jun; 35(3):198-201. PubMed ID: 15248104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Devic's neuromyelitis optica in an infant case.
    Yuksel D; Senbil N; Yilmaz D; Yavuz Gurer YK
    J Child Neurol; 2007 Sep; 22(9):1143-6. PubMed ID: 17890418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the spectrum of neuromyelitis optica: friend or foe?
    Behbehani R
    Curr Opin Ophthalmol; 2007 Nov; 18(6):459-62. PubMed ID: 18162996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.
    Hamnik SE; Hacein-Bey L; Biller J; Gruener G; Jay W
    Semin Ophthalmol; 2008; 23(3):191-200. PubMed ID: 18432545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.